ReviewNature medicine2013
Induced regeneration--the progress and promise of direct reprogramming for heart repair.
Review in Nature medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Copper homeostasis and cuproptosis in myocardial infarction: molecular mechanisms, treatment strategies and potential therapeutic targets.Frontiers in pharmacology · 2025Review
- Co-axial fibrous scaffolds integrating with carbon fiber promote cardiac tissue regeneration post myocardial infarction.Materials today. Bio · 2022Article
- Direct reprogramming as a route to cardiac repair.Seminars in cell & developmental biology · 2022Review
- MYCL-mediated reprogramming expands pancreatic insulin-producing cells.Nature metabolism · 2022Article
- The biological applications of DNA nanomaterials: current challenges and future directions.Signal transduction and targeted therapy · 2021Review
- Inhibition of EZH2 primes the cardiac gene activation via removal of epigenetic repression during human direct cardiac reprogramming.Stem cell research · 2021Article
- Beyond genomics-technological advances improving the molecular characterization and precision treatment of heart failure.Heart failure reviews · 2021Review
- Strategies and Challenges to Improve Cellular Programming-Based Approaches for Heart Regeneration Therapy.International journal of molecular sciences · 2020Review
- Co-culture of induced pluripotent stem cells with cardiomyocytes is sufficient to promote their differentiation into cardiomyocytes.PloS one · 2020Article
- Age-Related Pathways in Cardiac Regeneration: A Role for lncRNAs?Frontiers in physiology · 2020Review
- Xenogeneic-Free System for Biomanufacturing of Cardiomyocyte Progeny From Human Pluripotent Stem Cells.Frontiers in bioengineering and biotechnology · 2020Article
- Moving forward on the pathway of cell-based therapies in ischemic heart disease and heart failure - time for new recommendations?World journal of stem cells · 2019Article
- Human embryonic stem cell-derived cardiomyocyte therapy in mouse permanent ischemia and ischemia-reperfusion models.Stem cell research & therapy · 2019Article
- Functional ectodermal organ regeneration as the next generation of organ replacement therapy.Open biology · 2019Review
- Cardiac progenitor reprogramming for heart regeneration.Cell regeneration (London, England) · 2018Review
- Review
- Chimeric Adeno-Associated Virus-Mediated Cardiovascular Reprogramming for Ischemic Heart Disease.ACS omega · 2018Article
- Direct Cardiac Reprogramming: Progress and Promise.Stem cells international · 2018Review
- Genetic and Tissue Engineering Approaches to Modeling the Mechanics of Human Heart Failure for Drug Discovery.Frontiers in cardiovascular medicine · 2018Review
- Competent for commitment: you've got to have heart!Genes & development · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Regeneration of cardiac tissue has the potential to transform cardiovascular medicine. Recent advances in stem cell biology and direct reprogramming, or transdifferentiation, have produced powerful new tools to advance this goal. In this Review we examine key developments in the generation of new cardiomyocytes in vitro as well as the exciting progress that has been made toward in vivo reprogramming of cardiac tissue. We also address controversies and hurdles that challenge the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.